SHR 9839
Alternative Names: SHR-9839Latest Information Update: 08 Jul 2024
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Jun 2024 Shanghai Hengrui Pharmaceutical plans a phase I/II in Solid-tumours in China in June 2024 (Parentral) (NCT06474455)
- 04 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) (Parenteral), prior to December 2023 (Shanghai Hengrui Medicine pipeline, December 2023)
- 09 May 2023 Preclinical trials in Solid tumours in China (Parenteral) (NCT05836948)